Sarepta Therapeutics (SRPT) Stock Price, Quote, News & History

SPY777.31+0.01%QQQ758.56+0.11%BTC/USD82,872.01−0.49%DIA510.84−0.04%GLD376.62+0.20%TLT77.04−0.14%

Premium

Sarepta Therapeutics Inc (SRPT) Stock Price, Quote, News & History

SRPTNASDAQ

Trade with Public

$17.50

0.191.1%

Last update: Oct 7, 6:33 PM

$17.69

0.382.2%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$17.28

$17.50

Volume / Avg.

2.87M / 2.98M

Day Range

$16.98 - $17.67

52 Wk Range

14.68 - 25.32

Market Cap

$1.87B

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

28.86%

Days to Cover

8.02

Recent Sarepta Therapeutics, Inc. News

Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’

Cramer called Sarepta controversial, praised Avery Dennison and Ciena, favored ING and Santander, and declined to endorse FirstCash.

Avi Kapoor

Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday

U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.

Avi Kapoor

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.

Vandana Singh

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.

Avi Kapoor

Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket

iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while Focus Universal plunged 51.2%.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

111.01M

Investing Cash Flow (TTM)

100.85M

Financing Cash Flow (TTM)

-156.76M

Free Cash Flow (TTM)

74.97M

Capital Expenditure (TTM)

-36.04M

Net Change in Cash (TTM)

55.10M

Analyst Trends and Forecast

Apr

Jul

Sep

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.5

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.09B

PE Ratio (TTM)

PE Ratio (FWD)

17.48

PEG Ratio (TTM)

PS Ratio (TTM)

0.99

PB Ratio (TTM)

1.20

Earnings Yield % (TTM)

-9.07%

Earnings Yield % (FWD)

5.72%

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

25.95

Book Value / Share

$14.46

Company Debt

Total Debt

$847.62M

LT Debt

$847.62M

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$584.07M

Total Cash

$571.15M

Debt to Equity

0.68

Issuance of Debt (TTM)

-$159.07M

Repayment of Debt (TTM)

-$584.07M

Key Statistics

Open

$17.28

$17.50

Volume / Avg.

2.87M / 2.98M

Day Range

$16.98 - $17.67

52 Wk Range

14.68 - 25.32

Market Cap

$1.87B

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

28.86%

Days to Cover

8.02

About Sarepta Therapeutics Inc

Sector

Health Care

Industry

Biotechnology

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

FAQ

How do I buy Sarepta Therapeutics (SRPT) stock?

You can purchase shares of Sarepta Therapeutics (NASDAQ:SRPT) through any online brokerage.

View our list of the best stock brokerages

Who are Sarepta Therapeutics (SRPT) competitors?

Other companies in Sarepta Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).

What is the forecast, or price target, for Sarepta Therapeutics (SRPT) stock?

Sarepta Therapeutics has a consensus price target of $24.74.

What is the current price for Sarepta Therapeutics (SRPT)?

The stock price for Sarepta Therapeutics (NASDAQ: SRPT) is $17.69 last updated October 7, 2026 at 6:33 PM EDT.

Does Sarepta Therapeutics (SRPT) pay a dividend?

There are no upcoming dividends for Sarepta Therapeutics.

When is Sarepta Therapeutics (NASDAQ:SRPT) reporting earnings?

Sarepta Therapeutics does not have any upcoming earnings scheduled.

Is Sarepta Therapeutics (SRPT) going to split?

There is no upcoming split for Sarepta Therapeutics.

What sector and industry does Sarepta Therapeutics (SRPT) operate in?

Sarepta Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Sarepta Therapeutics Inc (SRPT) Stock Price, Quote, News & History

Sarepta Therapeutics (SRPT) Stock Price, Quote, News & History | Benzinga

Key Statistics

Recent Sarepta Therapeutics, Inc. News

Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’

Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket

Financials

Cash Flows

Analyst Trends and Forecast

Analyst Rating and Forecast

Valuation Metrics

Company Debt

Key Statistics

About Sarepta Therapeutics Inc

Edge Rankings

Stock Score Locked: Want to See it?

FAQ

How do I buy Sarepta Therapeutics (SRPT) stock?

Who are Sarepta Therapeutics (SRPT) competitors?

What is the forecast, or price target, for Sarepta Therapeutics (SRPT) stock?

What is the current price for Sarepta Therapeutics (SRPT)?

Does Sarepta Therapeutics (SRPT) pay a dividend?

When is Sarepta Therapeutics (NASDAQ:SRPT) reporting earnings?

Is Sarepta Therapeutics (SRPT) going to split?

What sector and industry does Sarepta Therapeutics (SRPT) operate in?

Key Statistics

Recent Sarepta Therapeutics, Inc. News

Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’

Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket

Financials

Cash Flows

Analyst Trends and Forecast

Analyst Rating and Forecast

Valuation Metrics

Company Debt

Key Statistics

About Sarepta Therapeutics Inc

Edge Rankings

Stock Score Locked: Want to See it?

Bulls vs Bears

FAQ

How do I buy Sarepta Therapeutics (SRPT) stock?

Who are Sarepta Therapeutics (SRPT) competitors?

What is the forecast, or price target, for Sarepta Therapeutics (SRPT) stock?

What is the current price for Sarepta Therapeutics (SRPT)?

Does Sarepta Therapeutics (SRPT) pay a dividend?

When is Sarepta Therapeutics (NASDAQ:SRPT) reporting earnings?

Is Sarepta Therapeutics (SRPT) going to split?

What sector and industry does Sarepta Therapeutics (SRPT) operate in?

Bulls vs Bears